Trial reportCirculation. Cardiovascular interventions2015
Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study.
Trial report in Circulation. Cardiovascular interventions, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03282266 (A Randomised, Single-blind, Sham Operation-controlled Study to Evaluate the Safety and Efficacy of the Pulmonary Artery Denervation for the Treatment of Pulmonary Arterial Hypertension), which is not on this map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Single-blind, Sham Operation-controlled Study to Evaluate the Safety and Efficacy of the Pulmonary Artery Denervation for the Treatment of Pulmonary Arterial Hypertension
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Meta-Analysis of Pulmonary Artery Denervation for Treatment of Pulmonary Hypertension.Brazilian journal of cardiovascular surgery · 2022Pooled it
- Novel device-based and catheter-directed therapies for heart failure with preserved ejection fraction.Cardiovascular intervention and therapeutics · 2026Review
- Clinical and Hemodynamic Effects of Pulmonary Artery Denervation in Pulmonary Hypertension Despite Optimized Pharmacotherapy: An Updated Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Targeted Drugs, PADN, and Transcatheter Closure for Atrial Septal Defect-Associated Pulmonary Hypertension.JACC. Case reports · 2026Article
- A Comparative Analysis of SegFormer, FabE-Net and VGG-UNet Models for the Segmentation of Neural Structures on Histological Sections.Diagnostics (Basel, Switzerland) · 2025Article
- Multi-Organ Denervation: The Past, Present and Future.Journal of clinical medicine · 2025Review
- Pulmonary Artery Denervation for Medication Refractory Pulmonary Hypertension (PARPH Study) - Study Protocol for a Prospective, Open-Label, Single-Arm Clinical Trial.Circulation reports · 2025Article
- Stereotactic body radiotherapy: a new non-invasive way to conduct pulmonary artery denervation.Frontiers in medicine · 2025Article
- High-intensity Focused Ultrasound-A New Choice to Conduct Pulmonary Artery Denervation.Journal of cardiovascular translational research · 2024Article
- Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies.Life (Basel, Switzerland) · 2024Review
- Autonomic nervous modulation: early treatment for pulmonary artery hypertension.ESC heart failure · 2024Review
- Noninvasive Stereotactic Radiotherapy for PADN in an Acute Canine Model of Pulmonary Arterial Hypertension.JACC. Basic to translational science · 2024Article
- Pulmonary Hypertension in Left Heart Diseases: Pathophysiology, Hemodynamic Assessment and Therapeutic Management.International journal of molecular sciences · 2023Review
- Sympathetic Denervation and Pharmacological Stimulation of Parasympathetic Nervous System Prevent Pulmonary Vascular Bed Remodeling in Rat Model of Chronic Thromboembolic Pulmonary Hypertension.Journal of cardiovascular development and disease · 2023Article
- Device-based neuromodulation for cardiovascular diseases and patient' s age.Journal of geriatric cardiology : JGC · 2022Article
- Future Perspectives of Pulmonary Hypertension Treatment.Acta Cardiologica Sinica · 2022Review
- Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: Long-term mortality after PADN stratified by functional class.AsiaIntervention · 2022Article
- The progress of pulmonary artery denervation.Cardiology journal · 2022Review
- Current status of pulmonary artery denervation.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe mechanisms underlying pulmonary arterial hypertension (PAH) are multifactorial. The efficacy of pulmonary artery denervation (PADN) for idiopathic PAH treatment has been evaluated. This study aimed to analyze the hemodynamic, functional, and clinical responses to PADN in patients with PAH of different causes. METHODS AND
resultsBetween April 2012 and April 2014, 66 consecutive patients with a resting mean pulmonary arterial pressure ≥25 mm Hg treated with PADN were prospectively followed up. Target drugs were discontinued after the PADN procedure. Hemodynamic response and 6-minute walk distance were repeatedly measured within the 1 year post PADN follow-up. The clinical end point was the occurrence of PAH-related events at the 1-year follow-up. There were no PADN-related complications. Hemodynamic success (defined as the reduction in mean pulmonary arterial pressure by a minimal 10% post PADN) was achieved in 94% of all patients, with a mean absolute reduction in systolic pulmonary arterial pressure and mean pulmonary arterial pressure within 24 hours of -10 mm Hg and -7 mm Hg, respectively. The average increment in 6-minute walk distance after PADN was 94 m. Worse PAH-related events occurred in 10 patients (15%), mostly driven by the worsening of PAH (12%). There were 8 (12%) all-cause deaths, with 6 (9%) PAH-related deaths.
conclusionsPADN was safe and feasible for the treatment of PAH. The PADN procedure was associated with significant improvements in hemodynamic function, exercise capacity, and cardiac function and with less frequent PAH-related events and death at 1 year after PADN treatment. Further randomized studies are required to confirm the efficacy of PADN for PAH. CLINICAL
trial registrationURL: http://www.chictr.trc.com.cn. Unique identifier: chiCTR-ONC-12002085.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.